Clinical Insights Into Novel Immune Checkpoint Inhibitors

The success of immune checkpoint inhibitors (ICIs), notably anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) as well as inhibitors of CTLA-4, programmed death 1 (PD-1), and programmed death ligand-1 (PD-L1), has revolutionized treatment options for solid tumors. However, the lack of respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jii Bum, Ha, Sang-Jun, Kim, Hye Ryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139127/
https://www.ncbi.nlm.nih.gov/pubmed/34025438
http://dx.doi.org/10.3389/fphar.2021.681320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139127/
https://www.ncbi.nlm.nih.gov/pubmed/34025438
http://dx.doi.org/10.3389/fphar.2021.681320

Ejemplares similares